Table 2.
Profiles of overlooked EGFR mutations.
| No | Gender | Smoking | Histology | EGFR mutation status | EGFR-TKI | Line of therapy | Response | TTF (m) | OS (m) | |
|---|---|---|---|---|---|---|---|---|---|---|
| #1 | Female | Non-smoker | Adenocarcinoma | A763_Y764insFQEA | ex20ins | Erlotinib | Second-line | SD | 5.9 | 19.9 |
| #2 | Male | Non-smoker | Adenocarcinoma | N771_P772insN | ex20ins | |||||
| #3 | Female | Non-smoker | Adenocarcinoma | V769_D770insGTV | ex20ins | |||||
| #4 | Female | Non-smoker | Adenocarcinoma | A763_Y764insFQEA | ex20ins | |||||
| #5 | Female | Non-smoker | Adenocarcinoma | L747_A750 > P | ex19del | |||||
| #6 | Male | Smoker | Adenocarcinoma | H773_V774insNPH | ex20ins | |||||
| #7 | Female | Non-smoker | Adenocarcinoma | T751_I759 > S | ex19del | Erlotinib | Second-line | SD | 10.1 | 33.8 |
| Osimertinib | Fifth-line | SD | 10.9 | – |